p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|18|8|749-772

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.18, Iss.8, 2018-10, pp. : 749-772

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

P53 Mdm2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 18, Iss. 30, 2012-10 ,pp. : 4668-4678

Bentham Science Publishers

Access to resources Recommend Favorite

Patented small molecule inhibitors of p53–MDM2 interaction

By Deng Jinxia   Dayam Raveendra   Neamati Nouri  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 2, 2006-02 ,pp. : 165-188

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule Inhibitors of p53/MDM2 Interaction

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 2, 2005-04 ,pp. : 159-165

Bentham Science Publishers

Access to resources Recommend Favorite

Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update

By  

Current Pharmaceutical Design, Vol. 17, Iss. 6, 2011-01 ,pp. : 536-559

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Protein-Protein Inhibitors for the p53-MDM2 Interaction

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 10, 2007-05 ,pp. : 952-960

Bentham Science Publishers

Access to resources Recommend Favorite